Nanomedicine approaches for in vivo cancer immunotherapy

Research output: Contribution to journalArticleAcademicpeer-review

1 Citation (Scopus)
165 Downloads (Pure)

Abstract

Tweetable abstract Commentary just out in @fsgnnm: unleashing the full potential of #cancer #nanomedicines by reprogramming the immunosuppressive #TME using #LNP #mRNA #vaccines and via promoting #trainedimmunity.

Original languageEnglish
Pages (from-to)1607-1611
Number of pages5
JournalNanomedicine
Volume18
Issue number23
Early online date19 Sept 2023
DOIs
Publication statusPublished - 1 Oct 2023

Funding

R van der Meel is supported by a Vidi grant (19681) from the Dutch Research Council (NWO). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Funders
Nederlandse Organisatie voor Wetenschappelijk Onderzoek

    Keywords

    • cancer nanomedicine
    • lipid nanoparticles
    • cancer vaccines
    • immunotherapy
    • immuno-oncology
    • mRNA
    • trained immunity
    • Immunosuppressive Agents
    • Neoplasms/therapy
    • Immunotherapy
    • Nanomedicine

    Fingerprint

    Dive into the research topics of 'Nanomedicine approaches for in vivo cancer immunotherapy'. Together they form a unique fingerprint.

    Cite this